DivestmentJun 9, 2026, 05:06 PM
Kyntra Bio Receives Final $4.0M Holdback from AstraZeneca
AI Summary
Kyntra Bio, Inc. announced it received the final $4.0 million holdback payment from AstraZeneca Treasury Limited on June 2, 2026. This payment completes all owed amounts under the Share Purchase Agreement related to the sale of Kyntra Bio's China operations, which closed on August 29, 2025. The total consideration for the sale was approximately $220 million, with $210 million paid at closing and the remaining $10.0 million subject to two holdbacks, both of which have now been fully satisfied.
Key Highlights
- Kyntra Bio received $4.0 million from AstraZeneca, completing the final holdback payment.
- This payment fully satisfies the second and final holdback from the February 20, 2025 Share Purchase Agreement.
- The sale of China operations to AstraZeneca closed on August 29, 2025, for approximately $220 million.
- Total consideration included $85 million in enterprise value and $135 million in net cash.
- An initial $210 million was paid at closing, with $10.0 million subject to holdbacks.
- The first holdback of $6.0 million, plus an additional $0.4 million, was received in November 2025.
- No indemnity claims were made, leading to the full release of the $4.0 million holdback.
Price Impact
More from KYNB